---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022531"
form_type: "8-K"
ticker: "AIXC"
cik: "0001460702"
company_name: "AIxCrypto Holdings, Inc."
filed_at: "2023-06-26T23:59:59+00:00"
generated_at: "2026-06-13T17:00:39.941014+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Qualigen Therapeutics President Amy Broidrick resigns; receives $360K annual severance for 12 months

## Summary
- Amy Broidrick resigned as President, Chief Strategy & Operating Officer and director effective June 16, 2023; departure not related to any disagreement.
- Separation agreement provides $16,636.79 for accrued salary/vacation and expense reimbursement.
- Severance of $360,000 annual salary continued for 12 months post-separation, plus COBRA coverage for 12 months.
- Broidrick has three months from separation to exercise vested stock options.

## SEC filing metadata
- accession: 0001493152-23-022531
- form_type: 8-K
- ticker: AIXC
- cik: 0001460702
- company_name: AIxCrypto Holdings, Inc.
- filed_at: 2023-06-26T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1460702/000149315223022531/0001493152-23-022531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1460702/000149315223022531/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022531
- JSON: https://secwatch.observer/filing/0001493152-23-022531.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022531.txt

## Key facts
- Executive change
  Amy Broidrick resigned as President, Chief Strategy and Operating Officer at AIxCrypto Holdings, Inc..
  - Action: resigned
  - Role: President, Chief Strategy and Operating Officer
  source text: Amy Broidrick, President, Chief Strategy and Operating Officer and a director of Qualigen Therapeutics, Inc. (the “Company”), provided her resignation to the Company, which became effective June 16, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1460702/000149315223022531/0001493152-23-022531-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.